The therapeutic monoclonal antibody market has grown significantly since the approval of the first product in 1986. As of November 2014, 47 monoclonal antibody products were approved in the US or Europe for various diseases, with many approved globally. At an approval rate of about four products per year, it is expected that 70 products will be on the market by 2020, with worldwide sales reaching nearly $125 billion. The market has expanded due to the development of various monoclonal antibody products, including full-length antibodies, antibody fragments, and antibody-drug conjugates. These products are now the dominant class in the biopharmaceutical market, with global sales reaching nearly $75 billion in 2013, accounting for about half of all biopharmaceutical sales. The market is expected to continue growing, with sales projected to reach $94 billion by 2017 and $125 billion by 2020. The growth of the monoclonal antibody market is driven by advances in understanding disease at the molecular level, the development of new targets for treatment, and the increasing demand for these products in global markets. Additionally, the expansion of the pharmaceutical market due to an aging population and rising living standards has contributed to the growth of the monoclonal antibody market. The market is also influenced by the increasing number of monoclonal antibody candidates in development, as well as the approval of biosimilars, which are similar but not identical to existing products. The first biosimilars, Remsima and Infectra, were approved in Europe in 2013, and their introduction is expected to increase the market's sales growth. The monoclonal antibody market is expected to continue growing, with a compound annual growth rate of 8% or more for the next several years. This growth is driven by the continued development of new products, the approval of biosimilars, and the increasing demand for monoclonal antibody products in various indications.The therapeutic monoclonal antibody market has grown significantly since the approval of the first product in 1986. As of November 2014, 47 monoclonal antibody products were approved in the US or Europe for various diseases, with many approved globally. At an approval rate of about four products per year, it is expected that 70 products will be on the market by 2020, with worldwide sales reaching nearly $125 billion. The market has expanded due to the development of various monoclonal antibody products, including full-length antibodies, antibody fragments, and antibody-drug conjugates. These products are now the dominant class in the biopharmaceutical market, with global sales reaching nearly $75 billion in 2013, accounting for about half of all biopharmaceutical sales. The market is expected to continue growing, with sales projected to reach $94 billion by 2017 and $125 billion by 2020. The growth of the monoclonal antibody market is driven by advances in understanding disease at the molecular level, the development of new targets for treatment, and the increasing demand for these products in global markets. Additionally, the expansion of the pharmaceutical market due to an aging population and rising living standards has contributed to the growth of the monoclonal antibody market. The market is also influenced by the increasing number of monoclonal antibody candidates in development, as well as the approval of biosimilars, which are similar but not identical to existing products. The first biosimilars, Remsima and Infectra, were approved in Europe in 2013, and their introduction is expected to increase the market's sales growth. The monoclonal antibody market is expected to continue growing, with a compound annual growth rate of 8% or more for the next several years. This growth is driven by the continued development of new products, the approval of biosimilars, and the increasing demand for monoclonal antibody products in various indications.